Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
Go back to Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis| AbbVie (NYSE: ABBV) | Delayed: 257.12 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $257.12 | 52 Week High | $68.12 | |||
| Open | $257.12 | 52 Week Low | $50.71 | |||
| Day High | $257.12 | P/E | 55.77 | |||
| Day Low | $257.12 | EPS | $4.61 | |||
| Volume | 5,153 | |||||
| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 217.15 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $217.15 | 52 Week High | $333.65 | |||
| Open | $217.15 | 52 Week Low | $223.02 | |||
| Day High | $217.15 | P/E | 27.80 | |||
| Day Low | $217.15 | EPS | $7.81 | |||
| Volume | 809 | |||||
